IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

In re: TESTERONE

REPLACEMENT THERAPY

PRODUCTS LIABILITY LITIGATION

THIS DOCUMENT RELATES TO:

Elmer Jordan v. AbbVie Inc., et al.,

Case No. 1:15-cv-03346

James Reinsel v. Endo Pharmaceuticals Inc., et al.,

Case No. 1:16-cv-00089

Craig Howard v. AbbVie Inc., et al.,

Case No. 1:16-cv-01771

Everett Adams v. Auxilium Pharmaceuticals, LLC, et al.,

Case No. 1:15-cv-11404

Estate of William Holland, v. AbbVie Inc., et al.,

Case No. 1:18-cv-03241

Gary Nash v. Auxilium Pharmaceuticals, LLC, et al.,

Case No. 1:16-cv-00731

Ted Porter v. Endo Pharmaceuticals Inc.,

Case No. 17-cv-03840

Donald Smith v. Auxilium Pharmaceuticals, LLC, et al.,

Case No. 1:15-cv-01340

Frank Miles v. Eli Lilly and Company, et al.,

Case No. 1:15-cv-08581

MDL No. 2545

Master Docket Case No. 1:14-cv-01748

Honorable Matthew F. Kennelly

CASE MANAGEMENT ORDER NO. 150 ORDER TO SHOW CAUSE WHY THE CASE SHOULD NOT BE DISMISSED WITH PREJUDICE FOR FAILURE TO COMPLY WITH CASE MANAGEMENT ORDER NO. 126

This matter is before the Court on the Endo Defendants' Motion For An Order To Show Cause Why The Case Should Not Be Dismissed With Prejudice For Failure To Comply With Case Management Order No. 126, filed April 12, 2019.

It is hereby ordered that counsel of record for each Plaintiff identified on Exhibit A below shall either file a stipulation dismissing the Endo Defendants with prejudice before May 7, 2019,

Case: 1:14-cv-01748 Document #: 2972 Filed: 04/19/19 Page 2 of 4 PageID #:76694

at 9:30 a.m. (twenty-one (21) days from this Order) or show cause in writing by no later than

May 9, 2019 why this case should not be dismissed under CMO 12, paragraph B.11 for failure to

comply with the CMO 126 obligations of paragraphs B.9. and B.10.

Plaintiffs' counsel are directed to immediately advise their clients in writing of this order

and to verify their compliance in writing in the individual case docket.

Status report regarding whether something was filed by each plaintiff, as discussed in

open court, is to be filed by counsel for Endo by May 16, 2019.

IT IS SO ORDERED.

Dated: 4/19/2019

MATTHEW K. KENNELLY

UNITED STATES DISTRICT JUDGE

2

Exhibit A – Unsubmitted Claims

	Comment Developed Linfo	D-4- E9-1	Plaintiff Last	Plaintiff First	Fulla Dafara Januar	Plaintiff's
1.	Illinois, Northern District 1:15-cv-03346	4/27/2015	Name Jordan	Name	Endo Defendants Endo Pharmaceuticals Inc.; Auxilium Pharmaceuticals Inc.; GlaxoSmithKline LLC	Simmons Hanly Conroy
	Illinois, Northern District 1:16-cv-00089	1/5/2016	Reinsel	James	Endo Pharmaceuticals Inc.; Auxilium Pharmaceuticals, Inc	Meyers & Flowers, LLC
	Illinois, Northern District 1:16-cv-01771	1/29/2016	Howard	Craig	Endo Pharmaceuticals Inc.; Auxilium Pharmaceuticals Inc.; GlaxoSmithKline LLC	Baron & Budd, P.C.
	Illinois, Northern District 1:15-cv-11404	12/17/2015	Adams	Everett	Auxilium Pharmaceuticals, Inc.; GlaxoSmithKline LLC	Meyers & Flowers LLC
	Illinois, Northern District 1:18-cv-03241	5/7/2018	Holland	Floria Greggs- Holand on behalf of the Estate of William Holland	Endo Pharmaceuticals Inc.	Bahe Cook Cantley & Nefzger PLC
	Illinois, Northern District 1:16-cv-00731	1/18/2016	Nash	Gary	Auxilium Pharmaceuticals, Inc.; GlaxoSmithKline LLC	Meyers & Flowers LLC
	Illinois, Northern District 1:17-cv-03840	5/23/2017	Porter	Ted	Endo Pharmaceuticals Inc.	Bahe Cook Cantley & Nefzger PLC

	Current Docket Info	Date Filed	Plaintiff Last Name	Plaintiff First Name	Endo Defendants	Plaintiff's Counsel
	Illinois, Northern District 1:15-cv-01340	1/23/2015	Smith	Donald	Auxilium Pharmaceuticals, Inc.	Girardi Keese
9.	Illinois, Northern District 1:15-cv-08581	9/29/2015	Miles	Frank	Endo Pharmaceuticals Inc.; Auxilium Pharmaceuticals Inc.; GlaxoSmithKline LLC	Baron & Budd, P.C.